Nursing care
Look-Alike Sound-Alike Drugs, explained for the bedside and the exam
Written and reviewed by Dana Whitfield, RN, MSN · 5 min read · Updated September 2026
Short answer
Look-alike sound-alike drugs are medications with names, packaging or dosage forms similar enough to cause mix-ups, such as hydralazine and hydroxyzine. Tall-man lettering, independent double-checks and separated storage exist specifically because these pairs keep causing real errors. They matter because the error happens before the five rights are even checked, at the point of reading or hearing the name.
Defining it precisely
Look-alike sound-alike, often abbreviated LASA, describes drug name pairs or groups that are easily confused either visually, on a label or in handwriting, or verbally, in a spoken order or handover. The confusion is not about the drug's action or indication; it is about the name itself being mistaken for another name before any clinical reasoning happens.
The classic example is hydralazine and hydroxyzine. Both are common, both start with hydr-, both are prescribed at similar-looking doses, and both have been mixed up often enough in practice that tall-man lettering, writing them as hydrALAZINE and hydrOXYzine, was introduced specifically to break the pattern recognition that causes the error. The pair is not confused because either drug is obscure. It is confused because the names are close and the drugs are common, which is exactly the combination that produces recurring errors rather than one-off ones.
The exceptions that matter
Not every similar-sounding pair carries equal risk, and treating them all identically misses where the danger actually concentrates. The highest-risk LASA pairs combine name similarity with dissimilar indications or dissimilar risk profiles, because a mix-up there produces a clinically significant wrong-drug error rather than a near-miss. Hydralazine, an antihypertensive, and hydroxyzine, an antihistamine and anxiolytic, is exactly this kind of pair: giving one for the other has a real effect on the patient, not a neutral one.
The exception worth remembering is that tall-man lettering only addresses the visual confusion, not the verbal one. A telephone or verbal order for hydralazine still sounds like hydroxyzine regardless of how the name is printed on the label. That is why verbal and telephone orders for LASA drugs require a read-back and spelling confirmation as a separate safeguard, not a substitute reliance on the packaging having been fixed already.
Using it to prioritise
Not every medication administration deserves the same level of scrutiny, and LASA status is one of the clearest signals for where to slow down. When a drug name on the MAR is one you know has a common look-alike or sound-alike partner, that is the moment to read the full name aloud, check it against the indication on the chart, and confirm the dose makes sense for that specific drug rather than assuming the pharmacy or prescriber has already caught any error.
This matters most at three points: transcribing a verbal order, retrieving a medication from a look-alike storage location, and administering when a patient's diagnosis does not obviously match the drug in hand. If a patient with no psychiatric or allergy history has hydroxyzine ordered where an antihypertensive would be expected clinically, that mismatch between drug and indication is the safety check working as intended, not a distraction from the task.
Traps in exam wording
Exam items testing this concept often embed the LASA pair inside a scenario rather than asking about it directly, expecting the candidate to notice a wrong-drug situation from context rather than from an explicit prompt. A stem describing a hypertensive patient who becomes drowsy and hypotensive after a dose the nurse assumed was an antihypertensive is testing recognition of a hydralazine-hydroxyzine mix-up, even though neither drug name may appear in the answer options.
A second common trap presents tall-man lettering in an answer option and asks what it prevents. The correct reasoning is that it reduces the risk of selecting the wrong drug at the point of reading the label, not that it corrects a dosing error, verifies patient identity, or replaces an independent double-check. Confusing tall-man lettering with a broader safety mechanism is the error the exam is checking for.
Examples from practice
Beyond hydralazine and hydroxyzine, well-documented LASA pairs include clonidine and clonazepam, celecoxib and citalopram, and hydromorphone and morphine, each pairing drugs with meaningfully different effects and risk profiles. Hydromorphone and morphine carry particular weight because both are high-alert opioids and a mix-up affects dose potency directly, since hydromorphone is significantly more potent than morphine at an equivalent volume.
In a medication room using automated dispensing cabinets, these pairs are often deliberately stored in non-adjacent bins or behind an additional confirmation prompt for exactly this reason. A nurse retrieving a LASA drug who sees the system flag a second confirmation step should treat that as a designed safeguard responding to a known error pattern, not as friction to click through.
Summary
Look-alike sound-alike drugs are a naming and perception problem, not a knowledge problem, which is why the safeguards target the point of reading or hearing the name rather than the point of clinical decision-making. Tall-man lettering, separated storage and verbal read-backs each address a different moment where confusion can enter, and none of them substitutes for the others.
The practical habit that covers most of this risk is simple: when a drug name feels familiar but the clinical picture does not quite fit, stop and verify the full name against the indication before administering. That single check, applied consistently at medication pairs like hydralazine and hydroxyzine, is what the tall-man lettering system was built to reinforce, and it is what most exam items in this area are ultimately testing.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
Why are hydralazine and hydroxyzine specifically used as the classic LASA example?
Both names begin with hydr-, both are common medications with similar-looking dosage strengths, and both have a documented history of being confused for one another in practice. That combination of frequency and similarity is exactly why tall-man lettering, hydrALAZINE and hydrOXYzine, was introduced for this pair.
Does tall-man lettering prevent verbal order errors too?
No, tall-man lettering is a visual safeguard on printed or electronic labels and only addresses confusion when the name is read. Verbal and telephone orders for LASA drugs still require a separate read-back and spelling confirmation because the name sounds identical regardless of how it is formatted in print.
What should a nurse do if a LASA drug seems mismatched with the patient's diagnosis?
Pause before administering, re-read the full drug name against the order and the patient's indication, and clarify with the prescriber or pharmacy if the mismatch remains unexplained. A drug that does not fit the clinical picture is one of the clearest bedside signals of a possible LASA mix-up.
Are all similar-sounding drug names equally dangerous?
No. The pairs that matter most combine name similarity with different indications or different risk profiles, since a mix-up there causes a genuine wrong-drug error rather than a low-consequence near-miss. Hydralazine and hydroxyzine, and hydromorphone and morphine, are examples where the consequences of confusion are clinically significant.
How does the NCLEX typically test LASA drug knowledge?
It usually embeds the confusion inside a clinical scenario, such as a patient reacting unexpectedly after a medication, rather than asking the candidate to define LASA directly. The expected reasoning is recognising a wrong-drug pattern from the clinical effect described, not recalling a definition.
More on pharmacology
Guides on this